Ontology highlight
ABSTRACT:
SUBMITTER: Gojo I
PROVIDER: S-EPMC5290001 | biostudies-literature | 2017 Feb
REPOSITORIES: biostudies-literature
Gojo Ivana I Beumer Jan H JH Pratz Keith W KW McDevitt Michael A MA Baer Maria R MR Blackford Amanda L AL Smith B Douglas BD Gore Steven D SD Carraway Hetty E HE Showel Margaret M MM Levis Mark J MJ Dezern Amy E AE Gladstone Douglas E DE Ji Jiuping Jay JJ Wang Lihua L Kinders Robert J RJ Pouquet Marie M Ali-Walbi Ismail I Rudek Michelle A MA Poh Weijie W Herman James G JG Karnitz Larry M LM Kaufmann Scott H SH Chen Alice A Karp Judith E JE
Clinical cancer research : an official journal of the American Association for Cancer Research 20160808 3
<h4>Purpose</h4>In preclinical studies, the PARP inhibitor veliparib enhanced the antileukemic action of temozolomide through potentiation of DNA damage. Accordingly, we conducted a phase 1 study of temozolomide with escalating doses of veliparib in patients with relapsed, refractory acute myeloid leukemia (AML) or AML arising from aggressive myeloid malignancies.<h4>Experimental design</h4>Patients received veliparib [20-200 mg once a day on day 1 and twice daily on days 4-12 in cycle 1 (days 1 ...[more]